Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics. 

The company presented early data on two candidates at the ASH meeting that use a less than two-day manufacturing process, YTB323 in diffuse large B-cell lymphoma and PHE885 in multiple myeloma.

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.